Real-world data reinforces the efficacy and tolerability of lenvatinib and pembrolizumab for treating recurring endometrial cancer.

This transcript has been edited for clarity. For more episodes, download the Medscape app or subscribe to the podcast on Apple Podcasts, Spotify, or your preferred podcast provider. Kathleen N. Moore, ...

DESTINY-Endometrial02 is a phase 3 trial assessing T-DXd as an adjuvant treatment for HER2-expressing endometrial cancer, ...

Ovarian germ cell tumors: 11-year experience in a Mexican university hospital. Background: The diagnosis of endometrioid carcinomas, mixed type, is based upon presence of a serous component varying ...

Phase III Trial of Standard-Dose Intravenous Cisplatin Plus Paclitaxel Versus Moderately High-Dose Carboplatin Followed by Intravenous Paclitaxel and Intraperitoneal Cisplatin in Small-Volume Stage ...

A phase 3 trial demonstrated progression-free survival improvements with Tecentriq-chemotherapy combination in patients with endometrial carcinoma. The treatment combination of Tecentriq (atezolizumab ...

The conversation often begins with subtle changes that women might initially dismiss as normal variations in their monthly cycle. Perhaps unusual bleeding between periods, or discharge that seems ...

"Endometrial hyperplasia and cancer are highly affected by obesity and lifestyle factors. Focusing on these factors in diverse communities will lead to our better understanding of these disparities.

Inside your pelvis is an organ that plays an important role in your period, ability to get pregnant, and carry a pregnancy. As with other parts of your body, sometimes cancer cells can grow there. The ...